Trial Profile

Phase I Clinical Study of UTAA06 Injection in Treatment of Patients With Advanced Malignant Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 29 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs UTAA-06 (Primary)
Indications Ovarian cancer; Solid tumours
Focus Adverse reactions; Therapeutic Use

Most Recent Events

12 Aug 2025 Status changed from recruiting to completed.
11 May 2024 According to a Bosengi media release, company announced the completion of (UTAA06) dosing to a solid tumor patient. On 7 May 2024, the team of Professor Shen Lin from the Department of Gastroenterology at Peking University Cancer Hospital completed the reinfusion of UTAA06 for ovarian cancer patient.
22 Apr 2024 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com